144 - Rapport Therapeutics, Inc. (0002012593) (Subject)

SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

144 - Rapport Therapeutics, Inc. (0002012593) (Subject)

144 - Rapport Therapeutics, Inc. (0002012593) (Subject)

144 - Rapport Therapeutics, Inc. (0002012593) (Subject)

10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)

8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

DEFA14A - Rapport Therapeutics, Inc. (0002012593) (Filer)

DEF 14A - Rapport Therapeutics, Inc. (0002012593) (Filer)

8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

Truist resumed coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $56.00

Raymond James initiated coverage of Rapport Therapeutics with a rating of Strong Buy and set a new price target of $66.00

Wells Fargo initiated coverage of Rapport Therapeutics with a rating of Overweight and set a new price target of $43.00

BTIG Research initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $47.00

Truist initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $44.00

H.C. Wainwright initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $31.00

Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform

TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy

Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00

Stifel initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET. Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL) – fireside chat on Monday, June 8, 2026, at 1:20 pm ET. Interested parties may access the live and archived webcasts of

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12  RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotech

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New data demonstrate that RAP-219 has a half-life of approximately 22 days RAP-219 was generally well tolerated throughout treatment and follow-up periods BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric dis

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago. Presentation Details Title: Efficacy and Tolerability of RAP-219, a Potential

RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) on strength of Phase 2a FOS dataPhase 2 trial in bipolar mania, development of a long-acting injectable, and other pipeline programs continued to progressEntered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar maniaEnded the

Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Rapport to receive upfront cash payment of $20 million, up to $308 million in potential development and commercial milestones and other payments, and mid-single-digit to mid-teens tiered royalties BOSTON and SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport") a clinical-stage biotechnology company dedicated to the discovery

BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: TD Cowen 46th Annual Healthcare Conference (Boston, MA) – presentation and fireside chat on Tuesday, March 3, 2026, at 3:10-3:40 pm ET. The Citizens Life Sciences Conference (Miami, FL) – presentation on Tuesday, March 10, 2026, at 2:15 pm ET. Leerink Global Healthcare Conference (Miami, FL) –

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026  On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial in bipolar mania, long-acting injectable, and other pipeline programs continuing to progress BOSTON and SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the presentation will be available in the "Investors" section of the company's website at: https://investors.rapportrx.com. About Rapport Therapeutics Rapport Therapeutics is a clinical-stag

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease severity  RAP-219 demonstrated meaningful improvements in patient-reported seizure severity among those with moderate or greater baseline impairment BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced new data and post hoc

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)Data support advancement of RAP-219 into Phase 3 registrational trialsCompany to host a conference call today at 8:00 a.m. ET BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today

BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13D - Rapport Therapeutics, Inc. (0002012593) (Subject)